Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 174

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 174
---
For any licensed product for which we are required to pay WuXi Biologics royalties, we will pay WuXi Biologics royalties on a licensed product-by-licensed product and region-by-region basis until the latest of (i) the
expiration of certain patents covering the relevant licensed product and (ii) an agreed period of time after the first commercial sale of that product in the applicable region. If generic competition occurs or there are no certain patents
covering the applicable antibody drug conjugate included in the licensed product, Aadi’s royalty obligations in the applicable region would be reduced as specified in the License Agreement.

Development, Commercialization and Manufacturing

Under the License Agreement, Aadi is wholly responsible for the development and commercialization of licensed products across all Programs, subject to certain
conditions. We also have sole control, at our expense, over all interactions with regulatory authorities with respect to licensed products.

In addition,
we control the manufacture and supply of licensed products and components thereof. Notwithstanding the foregoing, until such time as we elect to assume control of licensed product manufacturing, WuXi Biologics agreed to, directly or through a
certain affiliate, manufacture and supply our reasonable requirements of licensed product and components thereof pursuant to the terms of a commercially reasonable and mutually acceptable supply agreement to be executed by the parties at a later
date.

Term, Termination and Effects of Termination

If we do not pay WuXi Biologics the second tranche of the upfront payment (i.e., $38 million) within the time period set forth in the License Agreement, the
License Agreement will terminate at the end of such period. If we do pay such amount in accordance with the terms of the License Agreement, the License Agreement will remain in effect until expiration of the last to expire royalty term.

The License Agreement may be terminated in its entirety or on a
Program-by-Program basis by us or WuXi Biologics, if the other party materially breaches the License Agreement, subject to specified notice and cure provisions, or if
the other party experiences certain events of financial distress. In addition, WuXi Biologics may terminate the License Agreement on a Program-by-Program basis
if Aadi does not meet certain development milestones. Further, we may terminate the License Agreement in entirety, or on a region-by-region, licensed product-by-licensed product, or Program-by-Program basis for convenience by giving a specified
number of days prior written notice to WuXi Biologics.

In the event the License Agreement is terminated following